Next Article in Journal
Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer
Previous Article in Journal
Assessing the Impact of the COVID-19 Pandemic on Emergency Department Use for Patients Undergoing Cancer-Directed Surgeries
Case Report

Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis—The Adjuvant Role of Lifestyle Changes

1
Department of Hygiene, “Victor Babeș” University of Medicine and Pharmacy, Bd. Victor Babes No. 16, 300226 Timisoara, Romania
2
Department of Oncology—ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania
3
ANAPATMOL Research Center, “Victor Babeș” University of Medicine and Pharmacy, Eftimie Murgu Sq., No. 2, 300041 Timisoara, Romania
4
Department of Oncology—ONCOMED Outpatient Unit Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania
5
Department of Morphopathology, “Victor Babeş” University of Medicine and Pharmacy, Eftimie Murgu Sq., No. 2, 300041 Timisoara, Romania
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(3), 1890-1901; https://doi.org/10.3390/curroncol29030154
Received: 21 January 2022 / Revised: 8 March 2022 / Accepted: 8 March 2022 / Published: 10 March 2022
(This article belongs to the Topic Immunotherapy and Targeted Therapy in Breast Cancer)
The safety profile and effectiveness of existing anti-HER2-targeted therapies have not been evaluated in patients with breast cancer and visceral crisis. We report the case of a 26-year-old woman who was diagnosed with advanced HER2-positive breast cancer and initially treated with curative intent therapy in a neoadjuvant setting, using Trastuzumab and Pertuzumab in combination with Docetaxel; her cancer recurred two years later, with liver metastases and pulmonary lymphangitic carcinomatosis, causing visceral crisis. Furthermore, the patient’s clinical status worsened when she developed respiratory failure, hepatomegaly and a severe hepatocytolysis. Since the patient was free of disease more than six months, we started with Paclitaxel half dose because of the hepatic dysfunction, and we gradually reintroduced Trastuzumab and then Pertuzumab. In the meantime, the patient changed her lifestyle by increasing her consumption of fresh fruits and vegetables and fiber and reducing her intake of processed meat, dairy and sugar. As a result, the patient showed a significant improvement in her respiratory symptoms and liver tests in less than two months. Imaging reevaluation showed partial remission of liver metastases and pulmonary lymphangitic carcinomatosis. She underwent seven months of dual anti-HER2 blockade before relapsing cerebrally. Our results suggest that the sequential combination therapy with Trastuzumab, Pertuzumab and Paclitaxel presented in this study, associated with a healthy lifestyle, may be a good management for recurrent HER2-positive breast cancer with pulmonary visceral crisis and severe liver dysfunction. View Full-Text
Keywords: dual anti-HER2 blockade; HER2-positive breast cancer; visceral crisis; healthy lifestyle dual anti-HER2 blockade; HER2-positive breast cancer; visceral crisis; healthy lifestyle
Show Figures

Figure 1

MDPI and ACS Style

Badau, L.M.; Ciocoiu, A.D.; Oprean, C.M.; Segarceanu, N.A.; Gheju, A.; Vlaicu, B. Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis—The Adjuvant Role of Lifestyle Changes. Curr. Oncol. 2022, 29, 1890-1901. https://doi.org/10.3390/curroncol29030154

AMA Style

Badau LM, Ciocoiu AD, Oprean CM, Segarceanu NA, Gheju A, Vlaicu B. Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis—The Adjuvant Role of Lifestyle Changes. Current Oncology. 2022; 29(3):1890-1901. https://doi.org/10.3390/curroncol29030154

Chicago/Turabian Style

Badau, Larisa M., Andrei D. Ciocoiu, Cristina M. Oprean, Nusa A. Segarceanu, Adelina Gheju, and Brigitha Vlaicu. 2022. "Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis—The Adjuvant Role of Lifestyle Changes" Current Oncology 29, no. 3: 1890-1901. https://doi.org/10.3390/curroncol29030154

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop